---
document_datetime: 2025-09-11 17:23:12
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/otulfi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: otulfi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.580345
conversion_datetime: 2025-12-28 04:00:44.39232
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Otulfi

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                       |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------|
| Variation type IB /  | This was an application for a group of | 11/08/2025                          | 09/09/2025                                  | SmPC and PL                      | To update Sections 4.5 and 5.2 of the SmPC in |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000285631   | variations. C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Other variation - Accepted C.I.2.a (Type IB) - To update Sections 4.5 and 5.2 of the SmPC in order to add drug- drug interaction information, and to update Sections 4.8 and 5.1 of the SmPC with patient exposure numbers based on results from study CNTO1275CRD1003. The changes follow assessment of the same changes for the reference product, Stelara   | order to add drug-drug interaction information, and to update Sections 4.8 and 5.1 of the SmPC with patient exposure numbers based on results from study CNTO1275CRD1003. The changes follow assessment of the same changes for the reference product, Stelara (II/0107). To extend the indication to include the treatment of moderately to severely active Crohn's disease in paediatric patients weighing at least 40 kg, who have had an inadequate response to, or were intolerant to either conventional or biologic therapy. The PI is updated accordingly. The changes follow assessment of the same changes for the reference product, Stelara (II/0108). To include the needle gauge size in Section 6 of the SmPC for the 45 mg and 90 mg Otulfi solution for injection in a pre-filled syringe presentations (EU/1/24/1863/001, 002).   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                       | opportunity to implement editorial changes to align the PI with the QRD template. C.I.2.a (Type IB) - To extend the indication to include the treatment of moderately to severely active Crohn's disease in paediatric patients weighing at least 40 kg, who have had an inadequate response to, or were intolerant to either conventional or biologic therapy. The PI is updated accordingly. The changes follow assessment of the same changes for the reference product, Stelara (II/0108). C.I.z (Type IB) - To include the needle gauge size in Section 6 of the SmPC for the 45 mg and 90 mg Otulfi solution for injection in a pre-filled syringe presentations (EU/1/24/1863/001, 002). In addition, the MAH took the opportunity to update the PI with information on the polysorbate excipient, based on the Annex to the European Commission guideline on 'Excipients in the labelling and package   |            |     |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IA / EMA/VR/0000280806 | B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 23/06/2025 | N/A |